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Abstract
Objective To assess the long term effects of two different modes of
disease management (comprehensive self management and routine
monitoring) on quality of life (primary objective), frequency and patients’
management of exacerbations, and self efficacy (secondary objectives)
in patients with chronic obstructive pulmonary disease (COPD) in general
practice.
Design 24month, multicentre, investigator blinded, three arm, pragmatic,
randomised controlled trial.
Setting 15 general practices in the eastern part of the Netherlands.
Participants Patients with COPD confirmed by spirometry and treated
in general practice. Patients with very severe COPD or treated by a
respiratory physician were excluded.
Interventions A comprehensive self management programme as an
adjunct to usual care, consisting of four tailored sessions with ongoing
telephone support by a practice nurse; routine monitoring as an adjunct
to usual care, consisting of 2-4 structured consultations a year with a
practice nurse; or usual care alone (contacts with the general practitioner
at the patients’ own initiative).
Outcome measures The primary outcome was the change in COPD
specific quality of life at 24 months as measured with the chronic
respiratory questionnaire total score. Secondary outcomes were chronic
respiratory questionnaire domain scores, frequency and patients’
management of exacerbations measured with the Nijmegen telephonic
exacerbation assessment system, and self efficacy measured with the
COPD self-efficacy scale.
Results 165 patients were allocated to self management (n=55), routine
monitoring (n=55), or usual care alone (n=55). At 24 months, adjusted
treatment differences between the three groups in mean chronic
respiratory questionnaire total score were not significant. Secondary
outcomes did not differ, except for exacerbationmanagement. Compared
with usual care, more exacerbations in the self management group were
managed with bronchodilators (odds ratio 2.81, 95% confidence interval
1.16 to 6.82) and with prednisolone, antibiotics, or both (3.98, 1.10 to
15.58).
Conclusions Comprehensive self management or routine monitoring
did not show long term benefits in terms of quality of life or self efficacy
over usual care alone in COPD patients in general practice. Patients in
the self management group seemed to be more capable of appropriately
managing exacerbations than did those in the usual care group.
Trial registration Clinical trials NCT00128765.
Introduction
Chronic obstructive pulmonary disease (COPD) is a slowly
progressive lung disease characterised by deterioration of lung
function and quality of life and periods of acute exacerbation.
Its substantial prevalence— in 2005 one in 59 people in England
were recorded as having COPD diagnosed by a physician1—and
its huge social and economic impact make COPD amajor health
problem.2 Most patients with COPD have mild to moderate
disease and are treated in general practice.3 To face the burden
of COPD, well studied and effective management strategies are
essential, particularly in primary care.
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According to current COPD guidelines, symptoms and airflow
obstruction should be monitored regularly to guide modification
of treatment and to identify complications early.2 3 Routine
monitoring should contribute to achieving management goals
in COPD—that is, to delay disease progression and to alleviate
its manifestations.4 The responsibility for this management
strategy is largely with the healthcare professional, who relies
on protocols and acts as an expert. The effects of monitoring
routines on clinical outcomes such as health status seem to be
doubtful.4 In addition, whether care should be based on uniform
routine consultations or should be more tailored to individual
patient’s needs with a shared responsibility between physician
and patient has been questioned.5
Comprehensive self management programmes focus on the
needs of the individual patient. These programmes are based
on the presumption that effective modification of behaviour can
be attained only if patients’ self efficacy has been improved.6
Patients who have enough confidence in their ability to
successfully respond to certain events, such as at the time of an
exacerbation, can more easily modify and maintain the desired
behaviour. The behavioural modification should ultimately
result in improved clinical outcomes.7 COPD self management
programmes have shown positive effects on patients’ quality
of life and healthcare use in secondary care settings, but the
benefits in general practice are still inconclusive.8 9
Our primary objective was to assess the long term effects of
two different modes of COPD disease
management—comprehensive self management and routine
monitoring—on quality of life in COPD patients in general
practice. As secondary objectives, we assessed the effects on
frequency and patients’ management of exacerbations and on
self efficacy.
Methods
Study design
This was a 24 month, multicentre, investigator blinded, three
arm, parallel group, randomised controlled trial. After having
obtained signed informed consent, we randomly allocated
participating patients with COPD to comprehensive self
management as an adjunct to usual care, routine monitoring
through scheduled periodic monitoring visits as an adjunct to
usual care, or usual care alone.
Setting and participants
Fifteen general practices in the Netherlands (Nijmegen region)
recruited patients between June 2004 and September 2006. The
practices invited patients for an eligibility assessment by
following a standardised procedure in which they started inviting
patients on the basis of a list of all patients who (according to
the diagnostic codes in their electronic medical record system)
had been diagnosed as having COPD. The investigators
randomised the order in which the patients appeared on the list.
This assessment consisted of pre-bronchodilator and
post-bronchodilator spirometry,10 as well as collection of data
on sociodemographic characteristics, smoking habits, current
comorbid conditions, and current use of respiratory drugs.
Patients were eligible for the study if they were aged at least 35
years and their post-bronchodilator ratio of forced expiratory
volume in one second to forced vital capacity was less than
0.70. Exclusion criteria were post-bronchodilator forced
expiratory volume in one second below 30%predicted, treatment
by a respiratory physician, severe comorbid conditions with a
reduced life expectancy, inability to communicate in the Dutch
language, and objections to one or more of the modes of disease
management used in the study.
Randomisation and interventions
We randomised participants by using a computer generated two
block randomisation procedure with stratification on severity
of COPD (mild or moderate v severe airflow obstruction),2
smoking status (current v former smoker), and frequency of
exacerbations in the previous 24 months (<2 v ≥2
exacerbations). To ensure that the investigators were blinded
to individual treatment allocation, practice nurses informed the
patients of their allocation. We prevented potential treatment
contamination caused by provision of self management, routine
monitoring, and usual care within the same practice by using
strict protocols and registration forms and by providing the
required self management materials only for the patients
randomised to the self management group. At the end of the
study we reviewed the registration forms and the patients’
electronic medical files.
We randomly allocated patients to usual care, self management,
or routine monitoring. Usual care reflected the care for COPD
patients as provided bymost general practices in the Netherlands
in 2005. Patients received care from their general practitioner
at their own initiative when they consulted with aggravation of
symptoms. Patients in the usual care group did not receive any
care from the practice nurse—that is, they were not monitored
on a routine base and did not receive (parts of) a self
management programme.
Patients in the self management group received a translated and
modified version of the Canadian self management programme
“Living well with COPD.”11 Four Dutch general practitioners
and four patients with mild to moderate COPD who did not
participate in the trial evaluated the version used in the trial.
Unlike the original Canadian programme, our final version did
not include an exercise programme (table A of the web appendix
shows the differences). The self management programme
consisted of paper modules and a written exacerbation action
plan. Topics covered in the modules were COPD disease
knowledge, respiratory drugs, breathing techniques, managing
exacerbations, maintaining a healthy lifestyle, managing stress
and anxiety (optional), and home exercise (optional). The
individualised written exacerbation action plan covered early
recognition of and prompt action in the course of an
exacerbation. Actions included increase in bronchodilator use;
initiation of standing prescriptions for prednisolone, antibiotics
(if applicable), or both; or contacting the practice nurse or
general practitioner. The practice nurse of each participating
practice acted as case manager and applied the programme to
the individual patient in two to four sessions of approximately
one hour each, scheduled in four to six consecutive weeks. The
sessions took place in the general practice. The number of
sessions depended on the patient’s needs, but it was at least two.
Subsequently, the nurse called each patient six times during the
rest of the study period to reinforce self management skills. The
nurse was available for advice during business hours. Before
the study, all nurses were trained in how to apply the self
management programme. In addition, all nurses were observed
at least once by a respiratory nurse who was a member of the
study group and experienced in the self management
programme. The respiratory nurse also coached the practice
nurses by using a message board on a secured web based
application during the rest of the follow-up.
For participants in the routine monitoring group, practice nurses
scheduled routine monitoring visits in the general practice, on
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top of usual care. The contents of the monitoring visits were
based on the national and international COPD guidelines at time
of the study.12 13 At each consultation, the practice nurse
evaluated the severity of symptoms and limitations, health status,
adverse effects of and compliance with respiratory drugs, the
use of inhaler devices, and frequency of exacerbations; weight
and lung function were measured once a year. The contents of
the routine visits were not tailored to individual patient’s needs,
nor were self management elements such as the use of a written
exacerbation action plan included. The general practitioner
determined the individual frequency of monitoring, depending
on the severity of airflow obstruction and level of dyspnoea
(Medical Research Council dyspnoea score14), but it was at least
once a year with a maximum of four times a year.
Outcomes and follow-up
Our primary pre-specified outcome was the change from
baseline in health related quality of life after 24 months as
measured by the self administered chronic respiratory
questionnaire.15 16 This consists of 20 questions on a seven point
Likert-type scale (a higher score indicating better quality of
life), comprising a total score and four domain scores for
dyspnoea, mastery, fatigue, and emotion. Theminimal clinically
important difference for the questionnaire has been established
at 0.5 points.17 Secondary pre-specified outcomes were the
change in chronic respiratory questionnaire domain scores,
exacerbation frequency and management as recorded with an
automated call system, and total and five domain scores for self
efficacy as measured with the COPD self-efficacy scale.18 To
assess short term effects of the interventions, we analysed
differences in chronic respiratory questionnaire and COPD
self-efficacy scale total and domain scores at six months.
All participants visited the pulmonary function laboratory of
the Radboud University Nijmegen Medical Centre at baseline,
12 months, and 24 months. At six months and 18 months, a
trained lung function technician visited patients at home. During
all study visits, data were collected on smoking habits,
respiratory drugs, spirometry,10 health related quality of life,
and self efficacy. The data collected were not provided to the
practices.
We assessed frequency and patients’ management of
exacerbations with the Nijmegen telephonic exacerbation
assessment system (TEXAS).19 Patients were called once every
twoweeks on the day and at the time of their preference. Patients
answered (yes or no) to questions from an automated voice on
changes in respiratory symptoms and management of
exacerbations—that is, increase in bronchodilator use; initiation
of oral prednisolone, antibiotics, or both; and unscheduled
healthcare use in the two weeks before the call. TEXAS was
not part of any intervention and did not alert the patient when
an exacerbation was imminent. The validity of TEXAS as a
research tool has been shown previously.19 We defined
exacerbations as a change for at least two consecutive days in
either two or more major symptoms (dyspnoea, sputum
purulence, sputum amount) or any one major symptom plus at
least one minor symptom (colds, wheeze, sore throat, cough).20 21
Sample size calculation and statistical
analyses
Sample size calculation using analysis of variance showed that
we needed 55 patients in each treatment arm for 80% power
(α=0.05, two sided) to detect a minimal clinically important
difference in the change in the mean chronic respiratory
questionnaire total score of 0.5 points at 24 months with a
standard deviation of 0.8, a mean total score of 4.8 under the
null hypothesis,22 and an anticipated dropout rate of 25%. Our
primary analysis was based on the intention to treat principle
and included all available data for all participants.We compared
self management with usual care and routine monitoring with
usual care. We did not impute any missing data.
We show baseline characteristics as number (percentage), mean
(SD), or median (interquartile range). Because of repeated
measurements for each patient, we used generalised estimating
equations analyses with a compound symmetry structure and
including the data at all time points (including baseline) to
analyse differences within and between groups for the outcomes
chronic respiratory questionnaire total and domain scores and
COPD self-efficacy scale total and domain scores. We show
only the changes at six months (short term effects) and 24
months (long term effects). We used a generalised estimating
equations logistic regression model with compound symmetry
to estimate differences in clinically important improvements
(minimal clinically important difference ≥0.5) of chronic
respiratory questionnaire total scores between treatment arms.
We counted the number of exacerbations recorded by TEXAS.
A new exacerbation was distinguished from a previous one if
it was preceded by two weeks in which symptoms had not
worsened. We expressed exacerbation rates as number of
exacerbations per patient per year and compared them by using
weighted rate ratios.23We tested statistical significance by using
a negative binomial regression analysis with the patient as the
unit of analysis.24 We estimated differences in exacerbation
management by using generalised estimating equations logistic
regression models with compound symmetry and exacerbation
as the unit of analysis. To all models we added sex, age,
education level, long acting bronchodilator use, and inhaled
corticosteroid use as covariates. We used the statistical package
SAS version 9.2 for Windows for all analyses.
Results
Recruitment and patients’ characteristics
Figure 1⇓ shows the flow of patients through the study. Of the
748 patients whose general practitioner considered them to have
COPD, 326 (43.6%) did not meet our inclusion criterion of
post-bronchodilator ratio of forced expiratory volume in one
second to forced vital capacity of less than 0.70. No differences
were apparent between eligible patients who declined to
participate (n=120) and those who were randomised (n=165)
in terms of age (66.8 v 65.1 years, P=0.15), sex (61% v 63%
males, P=0.65), and post-bronchodilator forced expiratory
volume in one second as per cent predicted (70% v 68%,
P=0.38). Almost 16% (n=26) of the patients dropped out during
follow-up. Baseline characteristics did not differ between
dropouts and participants who completed follow-up. Table 1⇓
shows that at inclusion in the study, patients’ characteristics
were well balanced between the three study groups, except for
sex. Overall, more than half of the patients were male, most
patients had mild to moderate airflow obstruction, and a median
of 1.0 exacerbation was reported to the general practitioner in
the two years before the study.
Primary outcome
Figure 2⇓ shows the changes in COPD specific quality of life
(chronic respiratory questionnaire total score) for the self
management, routine monitoring, and usual care groups. At 24
months, the mean treatment differences between self
management and usual care and between routine monitoring
and usual care were not statistically significant (table 2⇓). More
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patients in the routine monitoring group than in the usual care
group showed a clinically important improvement (13/46 (28%)
v 8/44 (18%)) (fig 3⇓), but this difference was not statistically
significant (adjusted odds ratio 1.44, 95% confidence interval
0.61 to 3.38).
Secondary outcomes
Chronic respiratory questionnaire domain scores—Changes at
24months in the chronic respiratory questionnaire domain scores
were not statistically significant (table 2⇓), except for the
dyspnoea domain which showed improvement in the routine
monitoring group compared with the usual care group.
Exacerbation frequency andmanagement—153 patients reported
a total of 829 exacerbations. Frequency of exacerbations did
not differ between the three groups (table 3⇓). In the second
year of follow-up, more exacerbations in the self management
group than in the usual care group were managed by an increase
in bronchodilator use (odds ratio 2.81, 1.16 to 6.82) and by
starting prednisolone, antibiotics, or both (3.98, 1.10 to 15.58)
(table 4⇓). Also, in the second study year, more exacerbations
in the self management group than in the other two groups
tended to be reported to the general practitioner or nurse (not
statistically significant) (table 4⇓).
COPD self-efficacy scale total and domain scores—We found
no statistically significant changes or differences in patients’
self efficacy according to the COPD self-efficacy scale total
and domain scores at 24 months (table 2⇓).
Differences at six months—At sixmonths, differences in chronic
respiratory questionnaire domain scores and self efficacy total
and domain scores were not statistically significant (table B in
web appendix). More patients in the self management group
than in the usual care group achieved a clinically important
improvement in the chronic respiratory questionnaire total score
(16/49 (33%) v 11/45 (24%)) (fig 3⇓), but this was not
statistically significant (adjusted odds ratio 1.33, 0.52 to 3.4).
Process evaluation
In the self management group, patients received a mean of 3.4
(SD 1.5) sessions with the practice nurse with a mean duration
of 50.1 (12.8) minutes per session. Practice nurses had 190
telephone contacts with 44 patients (mean contacts 4.5 (1.6);
mean duration 15.3 (4.5) minutes). Seven (13%) patients did
not receive any session or telephone contact, and 48 (87%)
received two or more sessions. In the routine monitoring group,
patients received a mean of 3.4 (2.5) nurse consultations with
a mean duration of 27.4 (13.7) minutes per contact. Six (11%)
patients did not receive any consultation, and 42 (76%) patients
received two or more consultations. In the usual care group,
eight (15%) patients had one or more COPD related scheduled
contacts with the practice nurse and, therefore, deviated from
the study protocol.
Discussion
At 24 months, neither self management nor routine monitoring
showed significant benefits over usual care alone in terms of
disease specific quality of life, exacerbation frequency, or self
efficacy in patients with chronic obstructive pulmonary disease
in general practice. Compared with usual care, patients in the
self management group seemed to be more capable of taking
appropriate actions to manage their exacerbations—that is,
increasing their bronchodilator use (odds ratio 2.81, 95%
confidence interval 1.16 to 6.82) and starting prednisolone,
antibiotics, or both (3.98, 1.10 to 15.58).
Strengths and weaknesses of study
We used an existing, well studied (in secondary care), and
effective self management programme, Living Well with
COPD,11 instead of developing and testing a new one. This
answers the previous criticism on the use of different self
management programmes resulting in insufficient data for
meta-analysis and difficulties in formulating clear
recommendations.8Our study has a long follow-up (24months),
which follows the hypothesis that time is needed to change
behaviour and gain effects caused by self management in
patients with COPD.25
We should be careful with generalising our results to general
practice as a whole. Firstly, we excluded more than 60% of the
patients who had COPD according to their general practitioner
and had a recruitment assessment. In most cases, this was owing
to a post-bronchodilator ratio of forced expiratory volume in
one second to forced vital capacity of 0.70 or above. This
suggests that although treated as patients with COPD, a
substantial proportion of the COPD population in general
practice has been misdiagnosed according to current guidelines.
The recent awareness that spirometry has been underused in
general practice might improve its use and diminish the number
of patients misdiagnosed as having COPD.26 Secondly, of the
285 eligible patients, less than 60% were willing to participate.
Although these patients were comparable to those who declined
participation as regards sex, age, and disease severity (forced
expiratory volume in one second), we do not have information
on how representative the trial population was in terms of other
relevant factors such as baseline quality of life and exacerbation
history. Thirdly, almost 16% of the participants dropped out
during follow-up. However, baseline characteristics did not
differ between dropouts and participants who finished follow-up.
Also, we anticipated a dropout rate of 25% in our sample size
calculation. The dropout rate was lowest in the self management
group, which may suggest that patients in this group were more
motivated to adhere to COPD treatment because they were more
“involved” in the long term management of their disease.
Provision of self management, routine monitoring, and usual
care within the same general practice leads to a risk of treatment
contamination. Therefore, we used strict protocols and
registration forms for the practice nurses to minimise the risk
of treatment contamination, and we checked practices’
compliance with the protocols during and after the study. The
risk of contamination would have been smaller with a clustered
randomised trial design, but cluster randomised trials are more
complex to implement and require more participants and
practices to obtain equivalent statistical power.27
Interpretation with reference to other studies
To our knowledge, this is the first study that compares two
different methods of COPD management in patients in general
practice. In the self management group, care was tailored to
individual needs and close collaboration took place between the
patient and the healthcare professional. In the routine monitoring
group, care was based on uniform planned contacts and the
healthcare provider (practice nurse) acted as an expert and
strictly followed the contents of the COPDmonitoring protocol.
Routine monitoring did not affect quality of life, which confirms
the results of a previous trial on the effects of a COPD
monitoring routine in general practice.28 We could not confirm
the effects of the self management programme on disease
specific quality of life as previously observed in the Canadian
trial.11 Several possible explanations for this exist. Firstly, our
version of the programme was provided at a lower intensity
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than the original Canadian version—it had a maximum of four
individual sessions of 50 minutes each compared with weekly
one hour sessions for seven to eight weeks.11 Thus, less time
was available to spend on motivating patients to change their
behaviour. Secondly, the original Canadian programme also
included an exercise programme, which may have been an
important element of the programme.29 On the other hand, no
evidence exists to show that a hospital based extensive exercise
programme is effective for COPD patients in primary care; also,
we used the original modules that covered the importance of
physical activity and exercise at home. Thirdly, differences
existed between the study populations—the Canadian patients
hadmore severe COPD, weremanaged by respiratory specialists
in secondary care, and had been admitted to hospital for an acute
exacerbation at least once in the preceding year.11
The mean chronic respiratory questionnaire total score at
baseline in our study was high and comparable to those in other
primary care COPD studies.28 30 This limits the room for
improvement in our primary outcome (“ceiling effect”).
Exploration of whether patients with low baseline quality of
life scores had more benefit from the programme would be
interesting. However, the size of our study population limits
our ability to do meaningful subgroup analyses. In contrast with
self management trials that showed positive effects,11 31 we did
not use specialist respiratory nurses but practice nurses who
were (before the study) not familiar with the self management
programme.We noticed a wide heterogeneity among the nurses
in COPD education, experiences, and attitude, and we believe
that—despite our training and coaching—individual differences
may have influenced the ability of patients to adopt self
management behaviour.
In the process of self management, self efficacy and behavioural
change are important factors in the causal chain towards
potential health gains.7 In both the self management and routine
monitoring groups, patients did not show an improvement in
perceived self efficacy as measured with the COPD self-efficacy
scale.18 This is in line with a recent study.32 Compared with a
secondary care COPD population,33 baseline levels of COPD
self-efficacy scale total and domain scores in our study were
high, indicating a high level of confidence. As with quality of
life, this could have limited the room for improvement. In our
study, self management behaviour was reflected by exacerbation
management. In contrast with the routine monitoring group,
patients in the self management group received a tailored written
action plan for exacerbation management. Equipping COPD
patients with a written action plan has previously shown positive
effects on duration of exacerbation.34 Our finding that, in the
second year of the study, patients in the self management group
comparedwith patients in the usual care group showed improved
exacerbation management in terms of increasing their
bronchodilator use and particularly in terms of starting
prednisolone, antibiotics, or both suggests that an individualised
action plan and a long timeframe are both needed to establish
the effects of COPD self management programmes. Most
exacerbations remained unreported to the healthcare
professional. This is in line with other studies on exacerbation
management.35 36 Given the importance of timely management
of exacerbations to prevent complications and expedite recovery,
we propose that further studies on self management in general
practice should focus on effective exacerbation management as
the primary outcome.
Conclusions and recommendations for
practice
Patients with COPD who were treated in general practice did
not benefit from self management or routine monitoring over
usual care alone, except that patients who were enrolled in the
self management programme seemed to be more capable of
appropriately managing exacerbations. The chronic care
structure in Dutch general practice has significantly evolved
since the start of our study. More attention is now paid to the
other components of chronic care that increase the chance of
self management success.37Nowadays, there is a better prepared
delivery systemwith structured collaboration between healthcare
professionals, more and better equipped practice nurses, a
continuum of care to enhance self management behaviour, more
decision support from secondary care for the diagnosis and
management of COPD, and the development of clinical
information systems to support both the professional and the
patient. Policy makers and healthcare professionals should
consider this when interpreting the findings of our study.
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Tables
Table 1| Patients’ characteristics at study inclusion. Values are numbers (percentages) unless stated otherwise
Usual care (n=55)Routine monitoring (n=55)Self management (n=55)Characteristics
63.5 (10.3)65.8 (8.3)65.5 (11.5)Mean (SD) age (years)
28 (51)42 (76)37 (67)Male sex
8.0 (4.0-13.0)6.0 (3.0-11.0)7.0 (3.8-13.0)Median (interquartile range) COPD duration (years)
27 (49)35 (64)30 (55)Low educational level
18 (33)15 (27)16 (29)Current smoker
38 (69)42 (76)43 (78)Post-bronchodilator FEV1/FVC < lower limit of normal
67.0 (18.0)62.9 (14.4)66.3 (16.5)Mean (SD) post-bronchodilator FEV1 (% predicted)
0.5 (0-2.0)1.0 (0-2.0)1.0 (0-2.0)No (interquartile range) of previous GP diagnosed
exacerbations*
1.73 (0.76)1.87 (0.72)2.02 (0.94)Mean (SD) MRC dyspnoea score
Respiratory drug treatment:
19 (35)16 (29)11 (20)None
10 (21)14 (25)29 (53)Long acting bronchodilators
17 (31)21 (38)35 (64)Inhaled corticosteroids
Relevant comorbidities:
2 (4)2 (4)4 (7)Depression or anxiety
4 (7)7 (13)7 (13)Heart failure
1 (2)3 (5)4 (7)Cancer
COPD=chronic obstructive pulmonary disease; FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity; GP=general practitioner; MRC=Medical
Research Council.
*Unscheduled contacts with GP for worsening of respiratory symptoms in previous 24 months.
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Table 2| Primary and secondary clinical outcomes: within and between group differences at 24 months*. Values are mean (SD) unless
stated otherwise
Treatment difference at 24
monthsUsual care (UC) (n=55)
Routine monitoring (RM)
(n=55)Self management (SM) (n=55)
RM v UCSM v UC
Change at 24
months (95%
CI)Baseline
Change at 24
months (95%CI)Baseline
Change at 24
months (95%CI)Baseline
Primary outcome
0.16 (−0.11 to
0.42)
−0.22 (−0.49 to
0.042)
0.12 (−0.042 to
0.42)
5.26 (0.81)0.28 (0.088 to
0.47)
5.10 (0.77)−0.10 (−0.28 to
0.084)
5.11 (0.94)CRQ total
Secondary outcomes
0.027 (−0.33 to
0.38)
−0.31 (−0.66 to
0.039)
0.31 (0.062 to
0.56)
5.2 (1.08)0.34 (0.088 to
0.59)
5.18 (0.91)0.0026 (−0.24 to
0.24)
5.13 (1.02)CRQ
emotions
−0.088 (−0.44 to
0.26)
−0.20 (−0.55 to
0.14)
0.071 (−0.17 to
0.32)
4.91 (0.65)−0.017 (−0.26 to
0.23)
4.85 (0.77)−0.13 (−0.37 to
0.10)
4.75 (0.89)CRQ mastery
0.34 (−0.11 to
0.79)
−0.17 (−0.62 to
0.27)
−0.007 (−0.32 to
0.31)
5.04 (1.18)0.34 (0.019 to
0.65)
4.75 (1.18)−0.18 (−0.49 to
0.13)
4.79 (1.34)CRQ fatigue
0.40 (0.014 to
0.78)†
−0.16 (−0.54 to
0.21)
0.063 (−0.26 to
0.28)
5.82 (1.08)0.40 (0.13 to
0.67)
5.47 (1.29)−0.16 (−0.42 to
0.11)
5.68 (1.21)CRQ
dyspnoea
−0.15 (−0.62 to
0.32)
−0.17 (−0.64 to
0.30)
0.025 (−0.31 to
0.36)
3.6 (0.92)−0.12 (−0.45 to
0.20)
3.67 (0.86)−0.15 (−0.47 to
0.18)
3.53 (1.0)CSES total
0.13 (−0.30 to
0.56)
−0.053 (−0.48 to
0.38)
−0.22 (−0.53 to
0.09)
3.55 (0.84)−0.091 (−0.39 to
0.20)
3.51 (1.42)−0.27 (−0.57 to
0.025)
3.6 (0.92)CSES
negative
affect
−0.091 (−0.54 to
0.36)
−0.094 (−0.54 to
0.36)
−0.15 (−0.47 to
0.17)
3.69 (0.82)−0.24 (−0.55 to
0.07)
3.75 (0.8)−0.24 (−0.56 to
0.067)
3.67 (0.86)CSES
emotional
arousal
0.038 (−0.41 to
0.48)
−0.17 (−0.62 to
0.27)
0.12 (−0.20 to
0.45)
2.93 (0.84)0.16 (−0.15 to
0.47)
3.03 (1.01)−0.053 (−0.36 to
0.26)
3.01 (1.11)CSES
physical
exertion
−0.21 (−0.65 to
0.23)
−0.32 (−0.76 to
0.13)
0.13 (−0.19 to
0.45)
3.26 (0.9)−0.079 (−0.39 to
0.23)
3.36 (0.79)−0.18 (−0.49 to
0.12)
3.26 (1.0)CSES
weather/
environment
0.10 (−0.36 to
0.57)
−0.086 (−0.55 to
0.38)
−0.084 ( −0.42 to
0.25)
3.47 (0.92)0.019 (−0.30 to
0.34)
3.35 (0.91)−0.17 (−0.49 to
0.15)
3.34 (1.02)CSES
behavioural
risk factors
CRQ=chronic respiratory questionnaire; CSES=COPD self-efficacy scale.
*Generalised estimating equations analysis with compound symmetry structure and covariates of sex, age, educational level, long acting bronchodilator use, and
inhaled corticosteroid use, and including data at all time points.
†P=0.042.
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Table 3| Differences in exacerbation rate* per patient between groups
Rate ratio (95% CI)†
Usual care (UC) (n=48)Routine monitoring (RM) (n=55)Self management (SM) (n=53)Time RM v UCSM v UC
1.25 (0.98 to 1.58)1.10 (0.86 to 1.40)2.733.252.83Baseline to 12 months
1.15 (0.80 to 1.65)1.16 (0.81 to 1.67)2.172.382.4512-24 months
*Measured by automated telephonic exacerbation assessment system.
†Weighted rate ratios were tested for statistical significance by using negative binomial regression analyses.
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Table 4| Differences in patients’ management of exacerbations between groups. Values are numbers (percentages) unless stated otherwise
Odds ratio (95% CI)*Usual care (UC)
(n=48)
Routine monitoring
(RM) (n=55)
Self management
(SM) (n=53)Exacerbation management RM v UCSM v UC
(n=131)†(n=179)†(n=150)†Baseline to 12 months:
1.22 (0.60 to 2.48)1.70 (0.81 to 3.54)40 (31)65 (36)65 (43)Increased bronchodilator
1.28 (0.57 to 2.87)1.24 (0.43 to 3.57)13 (10)22 (12)16 (11)Prednisolone and/or antibiotics
1.08 (0.52 to 2.23)1.09 (0.42 to 2.81)18 (14)27 (15)20 (13)Unscheduled medical contact
(n=104)†(n=131)†(n=130)†12-24 months:
2.17 (0.95 to 4.95)2.81 (1.16 to 6.82)28 (27)56 (43)60 (46)Increased bronchodilator
1.71 (0.44 to 5.94)3.98 (1.10 to 15.58)5 (5)9 (7)20 (15)Prednisolone and/or antibiotics
0.93 (0.30 to 2.95)2.07 (0.60 to 7.15)12 (12)12 (9)24 (18)Unscheduled medical contact
*Estimated by using generalised estimating equations logistic regression models with compound symmetry with sex, age, educational level, long acting bronchodilator
use, and inhaled corticosteroid use as covariates.
†Number of exacerbations.
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Figures
Fig 1 Flow diagram of study. *Eligibility was assessed in general practice by measurement of pre-bronchodilator and
post-bronchodilator lung function10 and collection of data on sociodemographic characteristics, smoking habits, current
medical conditions, and current use of respiratory drugs. FEV1= forced expiratory volume in one second; FVC=forced vital
capacity
Fig 2 Changes in unadjusted means of chronic respiratory questionnaire total score during 24 months of follow-up for the
self management, routine monitoring, and usual care groups. Bars indicate 95% CIs
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Fig 3 Percentages of patients with clinically important improvements (≥0.5 improvement from baseline) in chronic respiratory
questionnaire (CRQ) total score during 24 months of follow-up
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